Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients.
Ivana SullivanPau RieraMarta AndrésAlbert AltésMargarita MajemRemei BlancoLaia CapdevilaAndrés BarbaAgustí BarnadasJuliana SalazarPublished in: Angiogenesis (2019)
Our findings reinforce the potential clinical value of germline variants in VEGFA and VEGFR2 and show for the first time variants in ITGAV and MAPK11 as promising prognostic markers in metastatic NSCLC patients receiving platinum-based chemotherapy.
Keyphrases
- copy number
- small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- ejection fraction
- newly diagnosed
- vascular endothelial growth factor
- genome wide
- peritoneal dialysis
- oxidative stress
- prognostic factors
- endothelial cells
- dna methylation
- locally advanced
- gene expression
- patient reported outcomes
- cell proliferation
- advanced non small cell lung cancer
- dna repair
- human health
- radiation therapy
- tyrosine kinase